A Study of ARRY-334543 and Gemcitabine in Patients With Advanced Cancer and Pancreatic Cancer

Array BioPharma

Status and phase

Completed

Phase 2

Phase 1

Conditions

Advanced Cancer

Pancreatic Cancer

Treatments

Drug: Gemcitabine, nucleoside analogue; intravenous

Drug: ARRY-334543, EGFR/ErbB2 inhibitor; oral

Study type

Interventional

Funder types

Industry

Identifiers

NCT00862524

ARRAY-543-206

Details and patient eligibility

About

This is a 2-phase study during which patients with advanced/metastatic solid tumors will receive investigational study drug ARRY-334543 and gemcitabine.

The study has 2 parts. In the first part of the study, Phase 1, patients with advanced/metastatic solid tumors will receive increasing doses of study drug in combination with gemcitabine in order to achieve the highest dose of study drug possible that will not cause unacceptable side effects. Patients will be followed to see what side effects the combination causes and what effectiveness the combination has, if any, in treating the cancer. Approximately 24 patients from the US will be enrolled in Part 1 (Completed).

In the second part of the study, Phase 2, patients with metastatic pancreatic cancer will receive the best dose of study drug, in combination with gemcitabine, determined from the first part of the study and will be followed to see what side effects the combination causes and what effectiveness the combination has, if any, in treating the cancer. Approximately 42 patients from the US will be enrolled in Part 2 (Withdrawn).

Enrollment

20 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion and exclusion criteria

Key Inclusion Criteria (Part 1):

Histologically or cytologically confirmed diagnosis of a solid tumor suitable for treatment with gemcitabine.
No more than 3 prior anticancer regimens for advanced disease.
Measurable or evaluable, nonmeasurable disease.
Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1.
Able to take and retain oral medications.
Additional criteria exist.

Key Exclusion Criteria (Part 1):

Uncontrolled or symptomatic brain metastases (if a patient has brain metastases and is on steroids, the steroid dose must have been stable for at least 30 days).
Treatment with prior chemotherapy within 21 days of first dose of study drug.
Requiring IV alimentation.
Pregnancy or lactation.
Known positive serology for the human immunodeficiency virus (HIV), hepatitis B and/or hepatitis C.
History of being unable to tolerate gemcitabine or any of its components.
Additional criteria exist.